Comparison

CY-09 European Partner

Item no. HY-103666-25mg
Manufacturer MedChem Express
CASRN 1073612-91-5
Amount 25 mg
Quantity options 100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 99.58
Formula C19H12F3NO3S2
Citations [1]Jiang H, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017 Nov 6;214(11):3219-3238.
Smiles OC(C1=CC=C(/C=C2SC(N(CC3=CC=CC(C(F)(F)F)=C3)C\2=O)=S)C=C1)=O
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Shipping condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
COVID-19-immunoregulation
Manufacturer - Targets
NOD-like Receptor (NLR)
Shipping Temperature
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight
423.43
Product Description
CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation[1].
Manufacturer - Research Area
Inflammation/Immunology
Solubility
DMSO : ≥ 150 mg/mL|H2O : < 0.1 mg/mL
Manufacturer - Pathway
Immunology/Inflammation
Isoform
NLRP3
Clinical information
No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close